Chamsi-Pasha MA, Kurrelmeyer KM. Noninvasive Evaluation of Symptomatic Women with Suspected Coronary Artery Disease. Methodist DeBakey Cardiovasc J. 2017;13(4):193-200.doi: 10.14797/mdcj-13-4-193
Cardiovascular disease (CVD) is the leading cause of death in the United States, yet several factors make it challenging to diagnose in women. Although women have more frequent chest pain than men, atypical symptoms such as nausea, dyspnea, and fatigue make it difficult to determine their risk of coronary artery disease (CAD) before testing. Current guidelines recommend exercise electrocardiography (ex-ECG) as the initial test in symptomatic women with intermediate pretest probability who can exercise and have a normal resting ECG; however, treadmill ex-ECG testing has a significantly lower positive predictive value in women. In addition, women often have nonobstructive CAD in conjunction with microvascular dysfunction and other cardiovascular abnormalities that can decrease the accuracy of all noninvasive tests. The following provides an overview of exercise ECG, echocardiography, SPECT imaging, and various other available modalities and examines their effectiveness in diagnosing and managing symptomatic women with suspected CAD.Keywords
coronary artery disease , women , ischemic heart disease , stress test , exercise ECG
Cardiovascular disease (CVD) is the leading cause of death among women in the United States.1 Ischemic heart disease (IHD), which includes both obstructive and nonobstructive coronary artery disease (CAD), acute coronary syndromes, and angina, makes up the majority of this mortality.14 The diagnosis of CAD in women is difficult for several reasons. Although the prevalence of CAD is significantly lower in women than in men, women have chest pain more frequently than men and have more atypical symptoms such as nausea, dyspnea, and fatigue, making it difficult to determine the pretest likelihood of CAD.5 Women frequently have nonobstructive CAD coexisting with microvascular or endothelial dysfunction, epicardial and microvascular spasm, myocardial bridging, and conduit vessel stiffening, all of which may contribute to myocardial ischemia. These factors decrease the diagnostic accuracy of all noninvasive tests.6 However, clinicians continue to rely heavily on the results of noninvasive tests to enhance their ability to correctly diagnose IHD in women.
Many types of noninvasive tests are available to clinicians, including exercise electrocardiography, exercise and pharmacologic echocardiography (echo), exercise and pharmacologic radionuclide myocardial perfusion imaging with single-photon emission computed tomography (SPECT) or positron emission tomography (PET), stress myocardial perfusion and wall motion magnetic resonance imaging (CMR), and coronary computed tomography angiography (CCTA). This review touches on the role of each of these modalities in the diagnosis, prognosis, and management of symptomatic women with suspected IHD.
Exercise electrocardiography (ex-ECG) is the least costly and most commonly used screening test for IHD.6 The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend ex-ECG for all symptomatic women at intermediate risk for IHD who can exercise > 5 METS and have a normal resting ECG.6,7 These recommendations are based on the fact that ex-ECG has a similar negative predictive value in women and men (78% and 81%, respectively) and provides important prognostic information, such as exercise capacity, heart rate recovery, and chronotropic response.6-9
Exercise capacity has been shown to be an independent predictor of death in women. For every 1 MET increase in exercise capacity, the Framingham Risk Score-adjusted mortality was reduced by 17% (P < .001).8 Impaired heart rate recovery, defined as < 12 beats/min drop in heart rate 1 minute after cessation of exercise, was an independent predictor of mortality in women (HR 1.6, P < .0001).10 Chronotropic incompetence, defined as failure to achieve 85% of the age-predicted maximum heart rate in the absence of beta blockade therapy, has also been associated with a poor prognosis in both women and men.11 The Duke Treadmill Score (DTS), which incorporates exercise capacity, ST segment response, and angina score index, has likewise been shown to predict mortality in women, with annual mortality rates of 0.25% and 5% for DTS scores ? 5 or ? -11, respectively.12
The ST segment response alone has been shown to be inaccurate in predicting obstructive CAD in women. A meta-analysis of 29 studies that included 3,392 women reported a sensitivity and specificity of 62% and 68%, respectively, with a positive predictive value of only 47%.13 Some factors that may contribute to the inaccuracy of the ST response as a predictive tool include a lower prevalence of obstructive CAD in women compared to men and ST changes due to estrogen, mitral valve prolapse, coronary artery vasospasm, and microvascular disease, which are all more prevalent in women than men.14,15
Multiple studies have demonstrated improved accuracy of stress echo over ex-ECG for diagnosing obstructive CAD in women. A meta-analysis from the Agency for Healthcare Research and Quality (AHRQ) that included 1,286 women undergoing exercise (treadmill or bicycle) or pharmacologic (dobutamine, dipyridamole, or adenosine) stress echo reported a sensitivity and specificity of 79% and 83%, respectively. Stress echo has also been shown to have comparable sensitivity and specificity for detecting CAD in both women and men.13
Exercise echo is recommended for symptomatic women at intermediate risk for CAD who have an abnormal resting ECG or an abnormal ex-ECG,16 while pharmacologic stress echo is recommended for the symptomatic, intermediate-risk women who cannot exercise.16 Dobutamine is the most commonly used pharmacologic stress agent simply because studies using a vasodilator agent (dipyridamole or adenosine) have reported a lower sensitivity.17 The American Society of Echocardiography recommends the use of echocardiographic contrast for optimizing visualization of the endocardial border, which in turn improves wall motion analysis when two or more endocardial segments are not visualized at rest (Figure 1).18 Unlike ex-ECG, SPECT, and PET, stress echo can identify other reasons for the patient’s symptoms, such as heart failure, valvular heart disease, pericardial diseases, pulmonary hypertension, or aortic dissection.6 Stress echo has been shown to effectively risk-stratify women into low- and high-risk groups. The event rate following a normal ex-echo is less than 1% annually. The annual event rate following a normal pharmacologic echo is slightly higher and likely reflects the increased comorbidities in this patient population. Stress echo allows clinicians to determine the extent of infarction or stress-induced ischemia, with ? 4 abnormal segments being associated with a high rate of future IHD events. Other high-risk stress echo features include resting left ventricular ejection fraction (LVEF) ? 40%, right ventricular ischemia, an increase in end-systolic size with stress, and a decrease in LVEF with stress.18
MYOCARDIAL PERFUSION IMAGING
Myocardial perfusion imaging (MPI) has been shown to have better accuracy compared to ex-ECG for diagnosing obstructive CAD in women.19 A 14-study meta-analysis from AHRQ that included 1,000 women undergoing exercise (treadmill or bicycle) or pharmacologic (dipyridamole, adenosine, or regadenoson) SPECT with technetium-99m ( 99mTc) or thallium (Tl-201) reported a sensitivity and specificity of 81% and 78%, respectively.13 Exercise MPI with SPECT is recommended for symptomatic women at intermediate risk for CAD who have an abnormal resting ECG or an abnormal ex-ECG. Pharmacologic MPI with SPECT is recommended for the symptomatic, intermediate-risk women who cannot exercise.16 Tl-201 is a low-energy radioisotope that is easily scattered and attenuated by densely fibrotic or large breasts. Different strategies have been proposed to improve the specificity of Tl-201 imaging in women—for example, using breast markers and prone imaging—but little improvement in specificity was seen. In addition to having higher energy and less scattering and attenuation, 99m Tc radiotracers allow simultaneous acquisition of ECG-gated images of ventricular function. This helps to distinguish breast attenuation defects from true fixed perfusion defects, as the latter are associated with abnormal wall thickening and motion. Although Tl-201 and 99mTc SPECT have similar sensitivities for detecting CAD, 99mTc SPECT imaging has superior specificity and therefore is recommended for use in women (Figure 2).19 Perfusion defects of ? 10% induced by 99mTc SPECT have been associated with a high risk of future IHD events. Other findings associated with high IHD risk include a summed stress score > 8, LV dilation, and peak- or post-stress LVEF < 45%.6
99m Tc SPECT effectively risk stratifies women into low- and high-risk groups.19 Like ex-echo, the annual event rate following a normal exercise 99mTc SPECT is less than 1%. The annual event rate following a normal pharmacologic 99mTc SPECT is approximately 2-fold higher. The event rate following an abnormal 99mTc SPECT is dependent not only on the amount of ischemic myocardium and LVEF but also on age, functional disability, and other high-risk clinical features such as peripheral artery disease, diabetes mellitus, chronic obstructive lung disease, prior stroke, and chronic kidney disease.6 Comparative studies between stress echo and SPECT have shown comparable diagnostic and prognostic ability in the same patient population as well as in several meta-analyses.18 ACC/AHA guidelines recommend limiting radiation exposure as much as possible, particularly in premenopausal women and older women who are at low risk for obstructive CAD; in this patient population, ex-ECG or stress echo is preferable. If stress echo is unavailable, techniques to limit radiation exposure to < 3 mSv, such as stress-only MPI, rest-stress MPI PET, dose-reduction CCTA, or CMR, are recommended.6
In comparative studies between SPECT and PET, PET has demonstrated a statistically significant improvement in specificity for diagnosing obstructive CAD in women.20 Although prognostic data for PET is limited, a recent meta-analysis indicated the event rate was 0.4% per year for a normal versus 11.5% per year for a moderately to severely abnormal stress Rb-82 PET.21 PET myocardial flow reserve remains an area of active research since it may be beneficial in detecting microvascular CAD and predicting future IHD events in women with nonobstructive CAD.22
CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY
A wealth of data on the diagnostic and prognostic value of coronary computed tomographic angiography (CCTA) in patients suspected of having CAD has recently emerged. CCTA is currently recommended for symptomatic patients with an intermediate pre-test probability of CAD and an equivocal stress test result.23 Compared to CMR, CCTA has a higher spatial resolution, is more widely available, and has better patient acceptance and shorter examinations.23 In addition, CCTA can help to ascertain luminal narrowing, plaque location, plaque burden, advanced plaque characterization (low attenuation, noncalcified, calcified, or mixed), and the presence of arterial remodeling (Figure 3), all of which are instrumental in determining the prognostic significance of nonobstructive CAD in women.24
A meta-analysis that included 474 symptomatic women, all of whom had no known CAD and who underwent CCTA, reported a sensitivity and specificity of 93% and 77%, respectively.13 This is similar to the sensitivity and specificity reported in studies that enrolled both men and women (85% – 99% and 64% – 90%, respectively). More importantly, there was no significant difference in the diagnostic accuracy of CCTA between the total 679 women and 1,173 men in these mixed-gender studies when compared to invasive angiography.6
In large multicenter registries, CCTA has been shown to effectively risk stratify women into low- and high-risk groups. For example, the CONFIRM registry reported outcomes on 23,854 symptomatic patients without known CAD, of which 12,128 were women. A normal CCTA was associated with a very low 0.28% annual mortality rate in both men and women. However, the mortality rate increased with the extent and severity of CAD, with a hazards ratio of 1.62 for nonobstructive disease, 2 for obstructive 1-vessel disease, 2.92 for obstructive 2-vessel disease, and 3.7 for obstructive 3-vessel or left main coronary artery disease, with obstructive disease being defined as greater than 50% stenosis.25 Likewise, the annualized event rate, defined as death and myocardial infarction, increased with the extent and severity of obstructive CAD and was not significantly different between men and women.26 In nonobstructive CAD, the extent of disease also predicts mortality; 3-vessel nonobstructive disease is associated with the worst prognosis, followed by 2- and 1-vessel disease.27 In one cohort study, the annualized event rate for patients with normal coronaries, nonobstructive CAD, and obstructive CAD was 0.2%, 1.2%, and 2.1%, respectively.28 Plaque composition also predicts prognosis in patients with nonobstructive CAD, where noncalcified plaques are associated with a higher risk of death over 6 years (9.6%) than mixed plaque (3.3%) and calcified plaque (1.4%).29 Another marker of high IHD risk in women is a coronary artery calcium score (CAC) 400. In a subset of 2,820 symptomatic patients from the CONFIRM registry who had nonobstructive CAD—defined as 0% to 49% stenosis and a calculated CAC score—CAC ? 400 was associated with a 13-fold increased risk of death compared to patients with a zero CAC score.30
With technological advances, CCTA can now use fractional flow reserve (CT FFR) to delineate the severity of obstructive lesions by combining anatomical data with functional assessment of the stenosis. The DEFACTO trial is one of three studies that compared CT FFR to invasive FFR, and it demonstrated improved diagnostic accuracy for detecting lesion-specific ischemia compared to anatomic assessment by CCTA alone.31
CARDIAC MAGNETIC RESONANCE IMAGING
Growing evidence over the past decade demonstrates that stress cardiac magnetic resonance imaging (CMR) has good diagnostic accuracy and cost-effectiveness when evaluating patients for IHD. When compared to CCTA, CMR provides better temporal resolution, is radiation-free, and can assess epicardial and microvascular disease by detecting subendocardial ischemia, which makes it an ideal imaging modality for women. Diagnostic images can be obtained even in obese patients, whereas stress echo and SPECT would be limited by image quality.
In CMR, administration of a pharmacologic stressor (adenosine, regadenoson, dobutamine) is typically followed by contrast-enhanced imaging using gadolinium-based agents to assess regional wall motion, first-pass perfusion, and early and late gadolinium enhancement (Figure 4). However, in those patients who cannot receive gadolinium-based agents due to severely impaired renal function, wall motion can still be assessed using CMR following administration of dobutamine in a dosing regimen similar to dobutamine stress echocardiography. Meta-analyses of stress myocardial perfusion and wall motion CMR studies using adenosine and dobutamine reported a sensitivity of 83 and specificity of 8%6 for diagnosing CAD in both men and women.32,33 In one meta-analysis that included 501 symptomatic women with no known CAD, stress CMR demonstrated a sensitivity of 72% and a specificity of 84%.13 A large single-center trial comparing stress CMR to stress MPI showed that CMR was more sensitive in women compared to men (88.7% vs 50.9%, respectively) and had superior diagnostic accuracy in both sexes.34
Stress CMR prognostic data is limited compared to other noninvasive modalities but continues to emerge. One study of 208 symptomatic women demonstrated an event-free survival of 100% over 4 years in those with a negative stress CMR.35 However, in another study of 168 women, a positive vasodilator stress CMR was associated with an annual event rate of 15%.36 An LVEF ? 40% has been identified as a marker of high IHD events in men and women and confers a hazard ratio of 4.1 for subsequent cardiovascular death and nonfatal MI compared to those with normal findings.37 In addition, the extent of ischemia on stress CMR has been shown to predict IHD events, with ? 3 abnormal or ischemic CMR segments being associated with high risk.6 Finally, infarct size and the amount of transmural myocardial necrosis measured by late gadolinium enhancement has been shown to predict not only poor LV recovery but also major adverse cardiovascular events and all-cause mortality independent of LVEF and LV volumes.38-40
Stress CMR perfusion may be useful in detecting microvascular disease in women, which is a common cause of chest pain. Several small studies evaluated patients with chest pain who had normal coronary arteries based on invasive angiography but abnormal functional stress tests. Two of the studies showed that subendocardial ischemia was frequently present on stress CMR,41,42 and another showed a notable association with increased IHD events such as anginal hospitalization and repeat catheterization.43
The noninvasive diagnosis of CAD in women has proven to be particularly challenging secondary to limitations of the currently available noninvasive tests and the lower prevalence and severity of CAD in women. Due to its low specificity, ex-ECG in women may lead to increased cost and risk if cardiac catheterization is pursued rather than further noninvasive testing. However, current guidelines recommend it as the initial test in symptomatic women with intermediate pretest probability who have a normal resting ECG and can exercise. The other noninvasive imaging modalities give similar diagnostic and prognostic information in women that is comparable to men and are recommended in symptomatic women with intermediate pretest probability who have an abnormal resting or ex-ECG or are unable to exercise. Guidelines also recommend that factors such as radiation exposure, patient preference, renal function, body habitus, and the need for structural, functional, or hemodynamic information be taken into account when choosing the appropriate diagnostic test.
- Because of recent technological advances in noninvasive stress testing procedures, comparative studies have demonstrated similar accuracy in women and men with the exception of treadmill exercise ECG testing, which is more accurate in men.
- Treadmill exercise ECG testing has similar negative predictive value in women and men, but the positive predictive value is significantly lower in women.
- Women with a positive treadmill exercise ECG should be referred for stress testing with imaging because of the low positive predictive value of treadmill exercise ECG testing.
- The appropriate stress test with imaging needs to be individualized for each patient, taking into account radiation exposure, patient preference, renal function, body habitus, and the need for structural, functional, or hemodynamic information.
The authors have completed and submitted the Methodist DeBakey Cardiovascular Journal Conflict of Interest Statement and none were reported.References
1. Lloyd-Jones D, Adams RJ, Brown TM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010 Feb 23;121(7):e46-e215.
2. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med. 1999 Jul 22;341(4):217-25.
3. Vaccarino V1, Krumholz HM, Yarzebski J, Gore JM, Goldberg RJ. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med. 2001 Feb 6;134(3):173-81 .
4. Shaw LJ, Shaw RE, Merz CN, et al.; American College of Cardiology-National Cardiovascular Data Registry Investigators. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation. 2008 Apr 8;117(14):1787-801.
5. Stangl V, Witzel V, Baumann G, Stangl K. Current diagnostic concepts to detect coronary artery disease in women. Eur Heart J. 2008 Mar;29(6):707-17.
6. Mieres JH, Gulati M, Bairey Merz N, et al.; American Heart Association Cardiac Imaging Committee of the Council on Clinical Cardiology; Cardiovascular Imaging and Intervention Committee of the Council on Cardiovascular Radiology and Intervention. Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: a consensus statement from the American Heart Association. Circulation. 2014 Jul 22;130(4):350-79.
7. Gibbons RJ, Balady GJ, Bricker JT, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee to Update the 1997 Exercise Testing Guidelines. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol. 2002 Oct 16;40(8):1531-40.
8. Gulati M, Pandey DK, Arnsdorf MF, et al.; Exercise capacity and the risk of death in women: the St James Women Take Heart Project. Circulation. 2003 Sep 30;108(13):1554-9.
9. Gulati M, Black HR, Shaw LJ, et al. The prognostic value of a nomogram for exercise capacity in women. N Engl J Med. 2005 Aug 4;353(5):468-75.
10. Vivekananthan DP, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery after exercise is a predictor of mortality, independent of the angiographic severity of coronary disease. J Am Coll Cardiol. 2003 Sep 3;42(5):831-8.
11. Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA. 1999 Feb 10;281(6):524-9.
12. Alexander KP, Shaw LJ, Shaw LK, Delong ER, Mark DB, Peterson ED. Value of exercise treadmill testing in women. J Am Coll Cardiol. 1998 Nov 15;32(6):1657-64.
13. Dolor RJ, Patel MR, Melloni C, et al. Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women. Comparative Effectiveness Review No. 58 (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) Rockville, MD: Agency for Healthcare Research and Quality; 2012 Jun. Report No.: 12-EHC034-EF.
14. Barrett-Connor E, Wilcosky T, Wallace RB, Heiss G. Resting and exercise electrocardiographic abnormalities associated with sex hormone use in women. The Lipid Research Clinics Program Prevalence Study. Am J Epidemiol. 1986 Jan;123(1):81-8.
15. Heinsimer JA, DeWitt CM. Exercise testing in women. J Am Coll Cardiol. 1989 Nov 15;14(6):1448-9.
16. Fihn SD, Gardin JM, Abrams J, et al.; American College of Cardiology. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012 Dec 18;126(25):3097-137.
17. Kim C, Kwok YS, Heagerty P, Redberg R. Pharmacologic stress testing for coronary disease diagnosis: A meta-analysis. Am Heart J. 2001 Dec;142(6):934-44.
18. Pellikka PA, Nagueh SF, Elhendy AA, Kuehl CA, Sawada SG; American Society of Echocardiography. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr. 2007 Sep;20(9):1021-41.
19. Mieres JH, Shaw LJ, Hendel RC, et al.; Writing Group on Perfusion Imaging in Women. American Society of Nuclear Cardiology consensus statement: Task Force on Women and Coronary Artery Disease–the role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease in women [correction]. J Nucl Cardiol. 2003 Jan-Feb;10(1):95-101.
20. Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol. 2006 Jan-Feb;13(1):24-33.
21. Nandalur KR, Dwamena BA, Choudhri AF, Nandalur SR, Reddy P, Carlos RC. Diagnostic performance of positron emission tomography in the detection of coronary artery disease: a meta-analysis. Acad Radiol. 2008 Apr;15(4):444-51.
22. Shaw LJ, Hage FG, Berman DS, Hachamovitch R, Iskandrian A. Prognosis in the era of comparative effectiveness research: where is nuclear cardiology now and where should it be? J Nucl Cardiol. 2012 Oct;19(5):1026-43.
23. Bluemke DA, Achenbach S, Budoff M, et al. Noninvasive coronary artery imaging: magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and intervention, and the Councils on Clinical Cardiology and Cardiovascular Disease in the Young. Circulation. 2008 Jul 29;118(5):586-606.
24. Baldassarre LA, Raman SV, Min JK, et al. Noninvasive Imaging to Evaluate Women With Stable Ischemic Heart Disease. JACC Cardiovasc Imaging. 2016 Apr;9(4):421-35.
25. Min JK, Dunning A, Lin FY, et al.; CONFIRM Investigators. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease. J Am Coll Cardiol. 2011 Aug 16;58(8):849-60.
26. Schulman-Marcus J, Hartaigh BÓ, Gransar H, et al: Sex-Specific Associations Between Coronary Artery Plaque Extent and Risk of Major Adverse Cardiovascular Events: The CONFIRM Long-Term Registry. JACC Cardiovasc Imaging. 2016 Apr;9(4):364-72.
27. Lin FY, Shaw LJ, Dunning AM, et al. Mortality risk in symptomatic patients with nonobstructive coronary artery disease: a prospective 2-center study of 2,583 patients undergoing 64-detector row coronary computed tomographic angiography. J Am Coll Cardiol. 2011 Jul 26;58(5):510-9.
28. Yiu KH, de Graaf FR, Schuijf JD, et al. Age- and gender-specific differences in the prognostic value of CT coronary angiography. Heart. 2012 Feb;98(3):232-7.
29. Ahmadi N, Nabavi V, Hajsadeghi F, et al. Mortality incidence of patients with nonobstructive coronary artery disease diagnosed by computed tomography angiography. Am J Cardiol. 2011 Jan;107(1):10-6.
30. Shah S, Bellam N, Leipsic J, et al.; CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter Registry) Investigators Prognostic significance of calcified plaque among symptomatic patients with nonobstructive coronary artery disease. J Nucl Cardiol. 2014 Jun;21(3):453-66.
31. Min JK, Leipsic J, Pencina MJ, et al. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA. 2012 Sep 26;308(12):1237-45.
32. Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2007 Oct 2;50(14):1343-53.
33. Hamon M, Fau G, Née G, Ehtisham J, Morello R, Hamon M. Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease. J Cardiovasc Magn Reson. 2010 May 19;12:29.
34. Greenwood JP, Motwani M, Maredia N, et al. Comparison of cardiovascular magnetic resonance and single-photon emission computed tomography in women with suspected coronary artery disease from the Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease (CE-MARC) Trial. Circulation. 2014 Mar 11;129(10):1129-38.
35. Jahnke C, Furundzija V, Gebker R, et al. Genderbased prognostic value of pharmacological cardiac magnetic resonance stress testing: head-to-head comparison of adenosine perfusion and dobutamine wall motion imaging. Int J Cardiovasc Imaging. 2012 Jun;28(5):1087-98.
36. Coelho-Filho OR, Seabra LF, Mongeon FP, et al. Stress myocardial perfusion imaging by CMR provides strong prognostic value to cardiac events regardless of patient’s sex. JACC Cardiovasc Imaging. 2011 Aug;4(8):850-61.
37. Hundley WG, Morgan TM, Neagle CM, Hamilton CA, Rerkpattanapipat P, Link KM. Magnetic resonance imaging determination of cardiac prognosis. Circulation. 2002 Oct 29;106(18):2328-33.
38. Tarantini G, Razzolini R, Cacciavillani L, et al. Influence of transmurality, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty. Am J Cardiol. 2006 Oct 15;98(8):1033-40.
39. Roes SD, Kelle S, Kaandorp TA, et al. Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. Am J Cardiol. 2007 Sep 15;100(6):930-6.
40. Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008 Jun;94(6):730-6.
41. Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med. 2002 Jun 20;346(25):1948-53.
42. Reynolds HR, Srichai MB, Iqbal SN, et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation. 2011 Sep 27;124(13):1414-25.
43. Johnson BD, Shaw LJ, Buchthal SD, et al.; National Institutes of Health-National Heart, Lung, and Blood Institute. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation. 2004 Jun 22;109(24):2993-9.